Intersect ENT Inc (XENT) : Aisling Capital scooped up 100,000 additional shares in Intersect ENT Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 12, 2016. The investment management firm now holds a total of 450,000 shares of Intersect ENT Inc which is valued at $6,489,000.Intersect ENT Inc makes up approximately 1.39% of Aisling Capital’s portfolio.
Other Hedge Funds, Including , Ubs Asset Management Americas Inc boosted its stake in XENT in the latest quarter, The investment management firm added 153,028 additional shares and now holds a total of 422,368 shares of Intersect ENT Inc which is valued at $6,170,796. Intersect ENT Inc makes up approx 0.01% of Ubs Asset Management Americas Inc’s portfolio.Teacher Retirement System Of Texas boosted its stake in XENT in the latest quarter, The investment management firm added 708 additional shares and now holds a total of 2,970 shares of Intersect ENT Inc which is valued at $43,808. Acadian Asset Management added XENT to its portfolio by purchasing 10,948 company shares during the most recent quarter which is valued at $171,336.
Intersect ENT Inc opened for trading at $15.63 and hit $15.94 on the upside on Monday, eventually ending the session at $15.84, with a gain of 1.34% or 0.21 points. The heightened volatility saw the trading volume jump to 1,38,335 shares. Company has a market cap of $451 M.
On the company’s financial health, Intersect ENT Inc reported $-0.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $-0.26. The company had revenue of $19.30 million for the quarter, compared to analysts expectations of $19.29 million. The company’s revenue was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.23 EPS.
Intersect ENT Inc. is a commercial-stage drug-device company. The Company develops drugs for patients with ear nose and throat conditions. The Company’s commercial products are the PROPEL and PROPEL mini drug-eluting implants for patients undergoing sinus surgery to treat chronic sinusitis. The Company is also developing PROPEL mini for use in frontal sinus surgery and is conducting clinical trials to evaluate two products RESOLVE and NOVA for treatment of patients in the physician’s office. The Company is developing the RESOLVE steroid releasing implant as an alternative treatment option for patients who are candidates for revision surgery that can be placed in the physician office setting during a routine visit. The Company is also developing NOVA a steroid releasing implant designed to fit the openings of the frontal and maxillary sinuses following ostial dilation using balloon sinuplasty.